title: 18F-alfatide PET/CT may predict short-term outcome of concurrent chemoradiotherapy in patients with advanced non-small cell lung cancer.
abstract: OBJECTIVE
  The study aims to investigate the role of18F-alfatide positron emission tomography/computed tomography (PET/CT) in predicting the short-term outcome of concurrent chemoradiotherapy (CCRT) in patients with advanced non-small cell lung cancer (NSCLC).
  
  
  METHODS
  Eighteen patients with advanced NSCLC had undergone18F-alfatide PET/CT scans before CCRT and PET/CT parameters including maximum and mean standard uptake values (SUVmax/SUVmean), peak standard uptake values (SUVpeak) and tumor volume (TVPETand TVCT) were obtained. The SUVmaxof tumor and normal tissues (lung, blood pool and muscle) were measured, and their ratios were denoted as T/NT (T/NTlung, T/NTbloodand T/NTmuscle). Statistical methods included the Two-example t test, Wilcoxon rank-sum test, Receiver-operating characteristic (ROC) curve analysis and logistic regression analyses.
  
  
  RESULTS
  We found that SUVmax, SUVpeak, T/NTlung, T/NTbloodand T/NTmusclewere higher in non-responders than in responders (P = 0.0024, P = 0.016, P < 0.001, P = 0.003, P = 0.004). According to ROC curve analysis, the thresholds of SUVmax, SUVpeak, T/NTlung, T/NTbloodand T/NTmusclewere 5.65, 4.46, 7.11, 5.41, and 11.75, respectively. The five parameters had high sensitivity, specificity and accuracy in distinguishing non-responders and responders. Multivariate logistic regression analyses showed that T/NTlungwas an independent predictor of the short-term outcome of CCRT in patients with advanced NSCLC (P = 0.032).
  
  
  CONCLUSIONS
  18F-alfatide PET/CT may be useful in predicting the short-term outcome of CCRT in patients with advanced NSCLC.
authors.affiliation: Department of Radiation Oncology, Shandong Cancer Hospital affiliated to Shandong University, No 440 Jiyan Road, Jinan, Shandong, 250117, China.|School of Medicine and Life Sciences, University of Jinan-Shandong Academy of Medical Sciences, Jinan, China.
authors.forename: Xiaohui
authors.initials: X
authors.lastname: Luan
authors.affiliation: Department of Radiology, Shandong Cancer Hospital affiliated to Shandong University, Jinan, Shandong, China.
authors.forename: Yong
authors.initials: Y
authors.lastname: Huang
authors.affiliation: Department of Oncology, Jining Infectious Diseases Hospital, Jining, Shandong, China.
authors.forename: Song
authors.initials: S
authors.lastname: Gao
authors.affiliation: Department of Radiology, Shandong Cancer Hospital affiliated to Shandong University, Jinan, Shandong, China.
authors.forename: Xiaorong
authors.initials: X
authors.lastname: Sun
authors.affiliation: Department of Radiation Oncology, Shandong Cancer Hospital affiliated to Shandong University, No 440 Jiyan Road, Jinan, Shandong, 250117, China.
authors.forename: Suzhen
authors.initials: S
authors.lastname: Wang
authors.affiliation: Department of Radiology, Shandong Cancer Hospital affiliated to Shandong University, Jinan, Shandong, China.
authors.forename: Li
authors.initials: L
authors.lastname: Ma
authors.affiliation: Department of Radiology, Shandong Cancer Hospital affiliated to Shandong University, Jinan, Shandong, China.
authors.forename: Xuepeng
authors.initials: X
authors.lastname: Teng
authors.affiliation: Department of Radiology, Shandong Cancer Hospital affiliated to Shandong University, Jinan, Shandong, China.
authors.forename: Hong
authors.initials: H
authors.lastname: Lu
authors.affiliation: Department of Radiation Oncology, Shandong Cancer Hospital affiliated to Shandong University, No 440 Jiyan Road, Jinan, Shandong, 250117, China.
authors.forename: Jinming
authors.initials: J
authors.lastname: Yu
authors.affiliation: Department of Radiation Oncology, Shandong Cancer Hospital affiliated to Shandong University, No 440 Jiyan Road, Jinan, Shandong, 250117, China. yuanshuanghu@sina.com.
authors.forename: Shuanghu
authors.identifier: http://orcid.org/0000-0002-3857-2800
authors.initials: S
authors.lastname: Yuan
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D002289:Carcinoma, Non-Small-Cell Lung / Q000000981:diagnostic imaging* / Q000628:therapy*; D059248:Chemoradiotherapy / Q000379:methods; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000000981:diagnostic imaging* / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D017063:Outcome Assessment, Health Care / Q000379:methods; D010456:Peptides, Cyclic; D000072078:Positron Emission Tomography Computed Tomography / Q000379:methods*; D011379:Prognosis; D019275:Radiopharmaceuticals; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D016896:Treatment Outcome
chemical_list: D010456:Peptides, Cyclic; D019275:Radiopharmaceuticals; C586680:alfatide II
keywords: 18F-alfatide; Concurrent Chemoradiotherapy; Integrin αvβ3; Non-small cell lung cancer; PET/CT